Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Central Institute of Epidemiology, Moscow
Vaccine reduces meningococcal risk in patients with immune deficiency
January 14th, 2004
A tetravalent meningococcal polysaccharide vaccine decreased the meningococcal infection risk in patients with late complement component deficiency. "Of 45 Russian patients with late complement component deficiency (LCCD) who experienced one to five meningococcal infections, 31 were immunized with a meningococcal A/C/Wl35/Y polysaccharide vaccine and were followed for three to eight years. Total and immunoglobulin (Ig) class specific concentration of antibodies to meningococcal polysaccharides in sera of LCCD patients increased significantly one month after vaccination and remained elevated for three years. Revaccination of LCCD patients three years after the first dose...
Source: Biotech Week (2004-01-14)
|
